Skip to main navigation

News
Investors
Careers
Contact

About Us
Our Approach
- What We Do
- Partnering
Patients & Providers
Science & Pipeline
Investors
Careers
- Culture
- Job Openings
Contact
Home
Menu Menu

Press Releases

Overview
Events & Presentations
Stock Information
Press Releases
Corporate Governance
SEC Filings
- Quarterly Results
Contact
Email Alerts

Year

CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics

02-22-2023
KemPharm Enhances Senior Management Team

01-31-2023
KemPharm Issues Letter to Shareholders

01-24-2023
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

01-18-2023
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

01-11-2023
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

01-09-2023
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

12-21-2022
KemPharm Announces Appointment of Christopher Posner as New Independent Director

11-29-2022
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

11-18-2022
KemPharm Reports Third Quarter 2022 Results

11-09-2022

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
…
Next page
Last page

About Us
Our Approach
- What We Do
- Partnering
Patients & Providers
Science & Pipeline
Investors
Careers
- Culture
- Job Openings
Contact
Home

© 2023 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use